Importantly, early intervention with the SGLT2 inhibitor dapagliflozin, initiated five weeks post-diabetes induction and three days post-tandem stenosis, mitigated these pathological changes, providing proof-of-concept evidence that SGLT2 inhibitors exert vasculoprotective and anti-atherosclerotic effects partially independent of their glucose-lowering properties [51]. The gene discussed is SLC5A2; the disease is diabetes mellitus.